Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 419

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 419
---
 molecular diagnostic company focused on developing noninvasive tests for early detection and monitoring of Mild Cognitive
Impairment, Alzheimer’s, Parkinson’s, other neurodegenerative diseases, and cancer. The proprietary technology developed at
the Company is based on quantitative analysis of circulating organ-enriched microRNAs in plasma. Short-term objectives of the Company
include the development of Lab-Developed tests (LDTs) under CLIA guidelines based on the identified miRNA signatures. The tests will be
used for screening, patient stratification, as well as disease and treatment monitoring. The Company has a patent portfolio that includes
United States patents, issued between 2014 and 2021 and set to expire between 2030 and 2037, and certain foreign counterparts.

NOTE 2 – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”)
for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes
required by GAAP in the United States for complete financial statements and should be read in conjunction with the annual financial statements.

Going Concern

The Company has a limited operating history and
incurred net losses of $614,405 and $1,318,431 for the years ended May 31, 2024 and 2023, respectively, and $483,710 for the nine months
ended February 28, 2025. The Company used net cash $308,914 in the year ended May 31, 2024 and $130,045 for the nine months ended February
28, 2025 for operating activities.

Since the inception of the Company in December
2009, the operations of the Company have been funded primarily through capital contributions of the founders of the Company as well as
grant funding, primarily received through the U.S. Department of Treasury and the National Institutes of Health (“NIH”). Management
believes this capital is insufficient to fund the Company’s operations for the next twelve months. Management does not anticipate
that the Company’s existing working capital alone will be sufficient to fund its operations through the successful development and
commercialization of products. As a result, the Company will need to raise additional capital to fund its operations and continue to conduct
activities to support its product development and commercialization activities. Management may raise additional funds by way of a public
or private offering or may